Inozyme Pharma : INZY Corporate Presentation July 2022

ı

Our Mission

Fulfill an unmet medical need with therapeutic breakthroughs in diseases of abnormal mineralization

July 2022

Legal Disclaimer

This presentation and any statements made orally during this presentation contain estimates and other statistical data made by independent parties and by us relating to market size and other data about our industry. This data involves a number of assumptions and limitations, and you are cautioned not to give undue weight to such data and estimates. In addition, projections, assumptions and estimates of our future performance and the future performance of the markets in which we operate are necessarily subject to a high degree of uncertainty and risk. Neither Inozyme Pharma, Inc. nor its affiliates, advisors or representatives make any representations as to the accuracy or completeness of that data or undertakes to update such data after the date of this presentation.

Forward-Looking Statement Disclaimer

Statements in this presentation about future expectations, plans, and prospects, as well as any other statements regarding matters that are not historical facts, may constitute forward-looking statements that involve substantial risks and uncertainties. These statements include, but are not limited to, statements relating to the initiation and timing of our clinical trials, the initiation and timing of our natural history studies, our research and development programs, the availability of preclinical study and clinical trial data, and the period over which we believe that our existing cash, cash equivalents and investments will be sufficient to fund our operating expenses.

The words "anticipate," "believe," "continue," "could," "estimate," "expect," "intend," "may," "might," "plan," "potential," "predict," "project," "should," "target," "will," "would" and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. We may not actually achieve the plans, intentions or expectations disclosed in these forward-looking statements, and you should not place undue reliance on these forward-looking statements. Actual results or events could differ materially from the plans, intentions and expectations disclosed in these forward-looking statements. For a discussion of risks and uncertainties, and other important factors, any of which could cause our actual results to differ from those contained in the forward-looking statements, see the "Risk Factors" section in our most recent Annual Report on Form 10-K filed with the Securities and Exchange Commission, as well as discussions of potential risks, uncertainties and other important factors, in the Company's most recent filings with the Securities and Exchange Commission.

In addition, the forward-looking statements included in this presentation represent our views as of the date of this presentation. We anticipate that subsequent events and developments will cause our views to change. However, while we may elect to update these forward-looking statements in the future, we specifically disclaim any obligation to do so. These forward-looking statements should not be relied upon as representing our views as of any date subsequent to the date of this presentation.

2

Investment highlights

Focused on rare and devastating diseases of abnormal mineralization

Initial focus on ENPP1 Deficiency and ABCC6 Deficiency, where there are no approved therapies

PPi is a well-established key mineralization biomarker

Preclinical findings demonstrated increasing PPi as a key predictive biomarker of therapeutic benefit in

predictive models with low PPi levels

Preliminary clinical data in lead indicationsısupport potential of INZ-701

Preliminary Phase 1/2 data in ENPP1 Deficiency and ABCC6 Deficiency showed INZ-701 had a favorable initial safety profile and

was generally well-tolerated in the first cohorts, rapidly and significantly increasing PPi

Planned expansion beyond initial indications

Long-term opportunity for expansion into non-genetic diseases of abnormal mineralization

(e.g., calciphylaxis, diseases of neointimal proliferation)

Well financed and poised for execution

Experienced rare disease team

Recently raised $73m gross proceeds in a follow-on offering

3

Management team and leadership

Axel Bolte, MSc, MBA

Co-founder, President and Chief Executive Officer

Kurt C. Gunter, MD

Chief Medical Officer

Yves Sabbagh, Ph.D.

Senior Vice President and Chief Scientific Officer

David Thompson, Ph.D.

Senior Advisor, Member of Scientific Advisory Board

Henric Bjarke

Senior Vice President and

Chief Operating Officer

Sanjay S. Subramanian, MBA

Senior Vice President and

Chief Financial Officer

Soojin Kim, Ph.D.

Senior Vice President and

Chief Technical Operations Officer

Board of Directors

Sarah Bhagat,	Axel Bolte,	Reinaldo M. Diaz,	Martin Edwards,
Ph.D.	MSc, MBA	MBA	M.D., MBA
Rob Hopfner,	Ed Mathers	Lynne Sullivan,	Doug Treco
Rph, Ph.D., MBA		MST	Ph.D., (Chair)

4

Abnormal mineralization and neointimal proliferation

5